RxAnte Revenue and Competitors

Portland, ME USA

Location

#3694

Growjo Ranking

Estimated Revenue & Valuation

  • RxAnte's estimated annual revenue is currently $11.5M per year.(i)
  • RxAnte's estimated revenue per employee is $140,000
  • RxAnte's total funding is $25.1M.

Employee Data

  • RxAnte has 82 Employees.(i)
  • RxAnte grew their employee count by 21% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$11.5M8221%$25.1MN/A
Add Company

Four out of five physician visits end with a prescription being written. Yet for many patients with chronic conditions, complications arise, health deteriorates, and costs spiral – all because potentially effective medications are not taken as prescribed. At RxAnte, we are passionate about improving health care, and we believe improving medication adherence is the most valuable place to start. RxAnte offers a new approach to improving population-level medication adherence efficiently. Born from decades of academic research, the RxAnte Solution is a patent-pending suite of analytics that: :Predicts medication adherence at the patient level ex ante (as early as the first filled prescription) :Prioritizes and targets the most cost-effective intervention(s) available for each patient :Monitors and evaluates the effectiveness of adherence programs :Measures and targets savings opportunities

keywords:Healthcare

$25.1M

Total Funding

82

Number of Employees

$11.5M

Revenue (est)

21%

Employee Growth %

N/A

Valuation

N/A

Accelerator

RxAnte News

2012-09-12 - RxAnte Raises Series A Financing

RxAnte, Inc., a McLean, VA-based health care improvement company providing a new and innovative approach for improving medication adherence, has raised a Series A financing. The round – whose amount was not disclosed – was led by Aberdare Ventures, with participation from the West Health Invest ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$20.6M82-37%N/A
#2
$14.8M8212%N/A
#3
$23.5M821%N/A
#4
$7.5M8221%N/A
#5
$22.1M825%N/A